Arcus Biosciences discontinues Phase 3 STAR-121 lung cancer trial for futility
Share
Listen to the news
Arcus Biosciences discontinues Phase 3 STAR-121 lung cancer trial for futility
  • Arcus Biosciences discontinued Phase 3 STAR-121 in first-line metastatic non-small cell lung cancer due to futility, based on Independent Data Monitoring Committee review of a pre-planned analysis on April 20, 2026.
  • Results were reviewed in that futility analysis, with no future presentation disclosed.
  • Domvanalimab with zimberelimab and chemotherapy did not show sufficient benefit versus pembrolizumab with chemotherapy to support continuing study.
  • Exploratory evaluation showed zimberelimab with chemotherapy performed in line on overall survival versus pembrolizumab with chemotherapy.
  • Arcus will also discontinue Phase 2 EDGE-Lung, with Gilead coordinating next steps for patients enrolled in both trials.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcus Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001724521-26-000021), on April 20, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending